ADC Therapeutics SA - notizie pubblicate 183 - letture 4.698
ADC THERAPEUTICS SA
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K
United states securities and exchange commission washington, d.c. 20549 form 6-k report of foreign private issuer pursuant to rule 13a-16 or 15d-16 under the securities exchange ac ...
ADC THERAPEUTICS SA
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on december 18, 2023 registration no. 333-__________ united states securities and exchange commission washington, d.c. 20549 fo ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
View all news adc therapeutics announces initial results from investigator-initiated phase 2 clinical trial evaluating zynlonta® in combination with rituximab in patients with rel ...
ADC THERAPEUTICS SA
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on december 4, 2023 registration no. 333-__________ united states securities and exchange commission washington, d.c. 20549 for ...
ADC THERAPEUTICS SA
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards - Form 6-K
Adc therapeutics receives nyse notice of non-compliance with continued listing standards lausanne, switzerland, november 7, 2023 - adc therapeutics sa (nyse: adct) today announced ...
ADC THERAPEUTICS SA
Consolidated Financial Statements - Form 6-K
Exhibit 99.1 unaudited ifrs condensed consolidated interim financial statements as of and for the three and nine months ended september 30, 2023. condensed consolidated interim sta ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
View all news adc therapeutics to participate in the jefferies london healthcare conference november 6, 2023 lausanne, switzerland, nov. 06, 2023 (globe newswire) -- adc therapeuti ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
View all news adc therapeutics announces abstracts accepted for presentation at the 65th ash annual meeting november 2, 2023 presentations to highlight clinical utility of zynlonta ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
View all news adc therapeutics to host third quarter 2023 financial results conference call on november 7, 2023 october 24, 2023 lausanne, switzerland, oct. 24, 2023 (globe newswir ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in September Investor Conferences
Lausanne, switzerland, sept. 05, 2023 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that ameet mallik, chief executive officer, will participate in two inves ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
Lotis-5: updated safety run-in results from phase 3 trial demonstrate 80% orr, 50% cr rate and median dor of 8 months with no new safety signals lotis-7: study design of trial eval ...
ADC THERAPEUTICS SA
Consolidated Financial Statements - Form 6-K
Exhibit 99.1 unaudited ifrs condensed consolidated interim financial statements as of and for the three and six months ended june 30, 2023. condensed consolidated interim statement ...
ADC THERAPEUTICS SA
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2q 2023 zynlonta®1 net sales increased 11% year-over-year; implemented new go-to-market strategy during the quarter to support growth operating expenses decreased 20%2 year-over-y ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
Lausanne, switzerland, aug. 01, 2023 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that it will host a conference call and live webcast on tuesday, august 8, ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti